BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Otsuka Can Block Generic Abilify as Court Rejects Appeal


1/15/2013 7:26:58 AM

The U.S. Supreme Court left intact a ruling that lets Otsuka Holdings Co. (4578)’s pharmaceutical unit block generic competition to its schizophrenia drug Abilify in the U.S. until April 2015. The justices today turned away an appeal by Canadian generic-drug maker Apotex Corp. The company challenged the patent for Abilify’s active ingredient, contending it would have been obvious to scientists based on known research. A U.S. appeals court rejected that argument. The drug generates sales of more than $5 billion a year, making it the fourth largest-selling drug in the U.S., Otsuka said, citing data from researcher IMS Health. New York-based Bristol-Myers Squibb Co. (BMY), which markets the drug with Otsuka, reported its share of Abilify sales was $2 billion in the first nine months of last year, or 15 percent of its revenue. Apotex said the active ingredient aripiprazole belongs to a class of compounds that have been known since the early 1980s and were covered by a patent that expired in 2005. The legal standard for deciding that question is too broad and “permits pharmaceutical companies to obtain or maintain patent monopoly rights over large portions of what belongs in the public domain,” Apotex argued in its high court appeal.

Read at Bloomberg
Read at Fox News

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->